by Plus Therapeutics | Feb 18, 2025 | GBM, LM, PBC, Uncategorized
Plus Therapeutics Secures $5.7 Million in Funding to Advance Cancer Research #PSTV News: Plus Therapeutics has successfully closed a private placement with $3.7 million in upfront proceeds and received a $2.0 million advance payment from the Cancer Prevention and...
by Plus Therapeutics | Feb 11, 2025 | GBM, LM, PBC, Uncategorized
Celebrating Strength and Resilience: Patient Appreciation Month At Plus Therapeutics, we are honored to celebrate #PatientAppreciationMonth and recognize the incredible strength, resilience, and courage of patients facing cancer. 🧡 Every day, we are inspired by those...
by Plus Therapeutics | Feb 4, 2025 | GBM, LM, PBC, Uncategorized
Honoring Progress and Hope on World Cancer Day 🔬 Today is #WorldCancerDay, a day dedicated to raising awareness, advancing research, and supporting those affected by cancer. At Plus Therapeutics, we recognize the unwavering dedication of patients, caregivers, and...
by Plus Therapeutics | Feb 1, 2025 | GBM, LM, PBC, Uncategorized
A Heartfelt Thank You to Our ReSPECT-GBM & ReSPECT-LM Clinical Trial Participants To every patient who has participated in the ReSPECT-GBM and ReSPECT-LM clinical trials: THANK YOU! 💙 Your courage and commitment are helping advance critical research for recurrent...
by Plus Therapeutics | Sep 4, 2024 | PBC
September is #ChildhoodCancerAwarenessMonth and we want to raise awareness for pediatric #braincancer resources 💛 These advocacy groups have a wealth of knowledge so please follow & share to #patients & #caregivers: (More can be found on our website:...
by Plus Therapeutics | Apr 29, 2024 | PBC
Following our EXCITING NEWS about our $3 Million award recommendation from the United States Department of Defense, we wanted to reshare our cancer guides for Pediatric High-Grade Glioma (https://www.respect-trials.com/patient-guide-hgg/) and Ependymoma...
Recent Comments